590 related articles for article (PubMed ID: 28645491)
21. Nivolumab in renal cell carcinoma: latest evidence and clinical potential.
Mazza C; Escudier B; Albiges L
Ther Adv Med Oncol; 2017 Mar; 9(3):171-181. PubMed ID: 28344662
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of immune checkpoint inhibitors in the treatment of kidney cancer oral metastasis. A case report.
Bruckmann M; Brenet E; Boulagnon-Rombi C; Louvrier A; Mauprivez C
J Stomatol Oral Maxillofac Surg; 2024 May; ():101913. PubMed ID: 38719194
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population.
Petrillo A; Tirino G; Zito Marino F; Pompella L; Sabetta R; Panarese I; Pappalardo A; Caterino M; Ventriglia A; Laterza MM; Morgillo F; Orditura M; Ciardiello F; Franco R; De Vita F
Onco Targets Ther; 2020; 13():867-876. PubMed ID: 32099391
[TBL] [Abstract][Full Text] [Related]
24. ASCO 2018: highlights of urothelial cancer and prostate cancer.
Pichler R; Horninger W; Heidegger I
Memo; 2018; 11(4):284-290. PubMed ID: 30595755
[TBL] [Abstract][Full Text] [Related]
25. Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors-2020 Update.
Jung G; Benítez-Ribas D; Sánchez A; Balaguer F
J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33142689
[TBL] [Abstract][Full Text] [Related]
26. Systematic Review on the Effectiveness and Outcomes of Nivolumab Treatment Schemes in Advanced and Metastatic Cervical Cancer.
Petre I; Vernic C; Petre I; Vlad CS; Sipos SI; Bordianu A; Luciana M; Dragomir RD; Fizedean CM; Daliborca CV
Diseases; 2024 Apr; 12(4):. PubMed ID: 38667535
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.
Hosonuma M; Hirasawa Y; Kuramasu A; Murayama M; Narikawa Y; Toyoda H; Baba Y; Isobe J; Funayama E; Tajima K; Shida M; Hamada K; Tsurui T; Ariizumi H; Ishiguro T; Suzuki R; Ohkuma R; Kubota Y; Horiike A; Sambe T; Tsuji M; Wada S; Kiuchi Y; Kobayashi S; Tsunoda T; Yoshimura K
Cancer Sci; 2024 Mar; 115(3):752-762. PubMed ID: 38254257
[TBL] [Abstract][Full Text] [Related]
28. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors.
Fukushima T; Kobayashi S; Ueno M
Jpn J Clin Oncol; 2024 May; ():. PubMed ID: 38769817
[TBL] [Abstract][Full Text] [Related]
29. Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma.
Yang S; Yang X; Hou Z; Zhu L; Yao Z; Zhang Y; Chen Y; Teng J; Fang C; Chen S; Jia M; Liu Z; Kang S; Chen Y; Li G; Niu Y; Cai Q
Heliyon; 2024 Apr; 10(7):e29215. PubMed ID: 38623200
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of nanocarriers for treatment of urologic cancers.
Wang AJY; Yan C; Reike MJ; Black PC; Contreras-Sanz A
Urol Oncol; 2024 Apr; 42(4):75-101. PubMed ID: 38161104
[TBL] [Abstract][Full Text] [Related]
31. Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers.
Mock A; Zschäbitz S; Kirsten R; Scheffler M; Wolf B; Herold-Mende C; Kramer R; Busch E; Jenzer M; Jäger D; Grüllich C
Cancer Immunol Immunother; 2019 Dec; 68(12):2005-2014. PubMed ID: 31701161
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review.
Kitchlu A; Jhaveri KD; Sprangers B; Yanagita M; Wanchoo R
Clin Kidney J; 2021 Sep; 14(9):2012-2022. PubMed ID: 34476087
[TBL] [Abstract][Full Text] [Related]
33. Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.
Tanegashima T; Shiota M; Fujiyama N; Narita S; Habuchi T; Fukuchi G; Takamatsu D; Oda Y; Miyake H; Takahashi M; Oya M; Tsuchiya N; Masumori N; Matsuyama H; Obara W; Shinohara N; Fujimoto K; Nozawa M; Ohba K; Ohyama C; Hashine K; Akamatsu S; Kamba T; Mita K; Gotoh M; Tatarano S; Fujisawa M; Tomita Y; Mukai S; Ito K; Tokunaga S; Eto M
J Immunol; 2024 May; ():. PubMed ID: 38758119
[TBL] [Abstract][Full Text] [Related]
34. Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: a systematic review of clinical trials evidence from solid and hematological tumors.
Alotaibi F; Alshammari K; Alotaibi BA; Alsaab H
Front Pharmacol; 2023; 14():1280591. PubMed ID: 38264532
[No Abstract] [Full Text] [Related]
35. Pembrolizumab-Induced Pancreatitis: Take It With a Grain of Salt.
Gajjar PC; Parmar P; Gajjar H; Upreti S; Shah M
Cureus; 2024 Apr; 16(4):e58417. PubMed ID: 38756289
[TBL] [Abstract][Full Text] [Related]
36. New treatment modalities with vaccine therapy in renal cell carcinoma.
Sönmez MG; Sönmez LÖ
Urol Ann; 2019; 11(2):119-125. PubMed ID: 31040593
[TBL] [Abstract][Full Text] [Related]
37. Research advances in the molecular classification of gastric cancer.
Shi D; Yang Z; Cai Y; Li H; Lin L; Wu D; Zhang S; Guo Q
Cell Oncol (Dordr); 2024 May; ():. PubMed ID: 38717722
[TBL] [Abstract][Full Text] [Related]
38. Checkpoint inhibitors in the treatment of urological malignancies.
Popovic LS; Matovina-Brko G; Popovic M
ESMO Open; 2017; 2(2):e000165. PubMed ID: 28761743
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy of Prostate Cancer: Facts and Hopes.
Bilusic M; Madan RA; Gulley JL
Clin Cancer Res; 2017 Nov; 23(22):6764-6770. PubMed ID: 28663235
[TBL] [Abstract][Full Text] [Related]
40. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Hammers HJ; Plimack ER; Infante JR; Rini BI; McDermott DF; Lewis LD; Voss MH; Sharma P; Pal SK; Razak ARA; Kollmannsberger C; Heng DYC; Spratlin J; McHenry MB; Amin A
J Clin Oncol; 2017 Dec; 35(34):3851-3858. PubMed ID: 28678668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
